Therefore, several markers including cell proliferation, PARP1/APE1 mRNA expression, γH2AX foci levels, chromosomal aberrations, and gene mutations were analyzed and correlated with cell survival of MDS/CMML and AML cells after treatment with talazoparib and APE1 inhibitor III, respectively. The gene discussed is APEX1; the disease is myelodysplastic syndrome.